Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

Jean‐Charles Nault, Yoann Martin, Stefano Caruso, Théo Z. Hirsch, Quentin Bayard, Julien Calderaro, Cecile Charpy, Christiane Copie‐Bergman, Marianne Ziol, Paulette Bioulac‐Sage, Gabrielle Couchy, Jean‐Frédéric Blanc, Pierre Nahon, Giuliana Amaddeo, Nathalie Ganne‐Carrie, Guillaume Morcrette, Laurence Chiche, Christophe Duvoux, Sandrine Faivre, Alexis Laurent, Sandrine Imbeaud, Sandra Rebouissou, Josep M.

Patients' Perspectives on Early Liver Transplantation in Alcohol‐Related Liver Disease

Eric Wong, Paul D. Mullins, Jean‐Philippe Wallach, Eric M. Yoshida, Sigfried R. Erb, Jo‐Ann Ford, Charles H. Scudamore, Vladimir Marquez – 17 June 2019 – Liver transplant programs in Canada require a period of 6 months of abstinence from alcohol before considering a patient with liver disease secondary to alcohol for transplantation.

Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro‐scalable Hepatic Co‐culture System

Benjamin Y. Winer, Jenna M. Gaska, Gabriel Lipkowitz, Yaron Bram, Amit Parekh, Lance Parsons, Robert Leach, Rohit Jindal, Cheul H. Cho, Anil Shrirao, Eric Novik, Robert E. Schwartz, Alexander Ploss – 17 June 2019 – Hepatitis B virus (HBV) remains a major global health problem with 257 million chronically infected individuals worldwide, of whom approximately 20 million are co‐infected with hepatitis delta virus (HDV).

LiverLearning®: Clinical Hepatology Update Conference 2019

** VIEW ONLY CONTENT . The Clinical Hepatology Update 2019 enduring course will be available soon. It will be available under the "On-Demand Accredited Activities". ** The Clinical Hepatology Update conference is designed for all medical professionals who manage care for patients with liver disease, including nurse practitioners, physician assistants, RNs, primary care physicians, medical students and GI or hepatology trainees. The conference will provide an update and review of the evolving practices in the clinical management of liver diseases.

Does Donor Allograft Microsteatosis Matter? Comparison of Outcomes in Liver Transplantation With a Propensity‐Matched Cohort

Kristopher P. Croome, David D. Lee, Sarah Croome, Raouf E. Nakhleh, Peter Abader Sedki Senada, David Livingston, Maria Yataco, C. Burcin Taner – 12 June 2019 – It has been suggested that microsteatosis does not negatively impact graft survival following liver transplantation (LT). The present study represents the largest series on donor livers with significant microsteatosis and investigates the impact of microsteatosis on perioperative factors such as postreperfusion syndrome (PRS), early allograft dysfunction (EAD), and postoperative renal dysfunction.

Depletion of TRRAP Induces p53‐Independent Senescence in Liver Cancer by Down‐Regulating Mitotic Genes

Suet‐Yan Kwan, Ankur Sheel, Chun‐Qing Song, Xiao‐Ou Zhang, Tingting Jiang, Hien Dang, Yueying Cao, Deniz M. Ozata, Haiwei Mou, Hao Yin, Zhiping Weng, Xin Wei Wang, Wen Xue – 12 June 2019 – Hepatocellular carcinoma (HCC) is an aggressive subtype of liver cancer with few effective treatments, and the underlying mechanisms that drive HCC pathogenesis remain poorly characterized. Identifying genes and pathways essential for HCC cell growth will aid the development of new targeted therapies for HCC.

Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals

George N. Ioannou, Pamela K. Green, Kristin Berry, Solomon A. Graf – 11 June 2019 – It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies.

Direct‐Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis

Camila C. Simoes, Omar A. Saldarriaga, Netanya S. Utay, Ashley E. Stueck, Sheharyar K. Merwat, Shehzad N. Merwat, Thomas D. Schiano, Maria Isabel Fiel, Heather L. Stevenson – 8 June 2019 – Patients with hepatitis C virus (HCV) often have elevated serum markers and histologic features of autoimmune hepatitis (AIH). We evaluated an HCV‐positive (HCV+) study group that had elevated serum markers of AIH before starting direct‐acting antiviral (DAA) therapy (n = 21) and compared them to an HCV+ control group that did not have laboratory studies suggesting AIH (n = 21).

Tumor‐Specific Transcripts Are Frequently Expressed in Hepatocellular Carcinoma With Clinical Implication and Potential Function

Qiupeng Zheng, Jingjing Zhao, Hui Yu, Huajie Zong, Xigan He, Yiming Zhao, Yan Li, Yu Wang, Yichao Bao, Yuchen Li, Bing Chen, Weijie Guo, Yilin Wang, Zhiao Chen, Yingjun Zhao, Lu Wang, Xianghuo He, Shenglin Huang – 7 June 2019 – Hepatocellular carcinoma (HCC) is a highly lethal cancer and its underlying etiology remains understudied. The immense diversity and complexity of the cancer transcriptome hold the potential to yield tumor‐specific transcripts (TSTs).

Subscribe to